903556-85-4 Usage
Uses
Used in Neuroscience Research:
5-(Aminomethyl)benzo[d]oxazol-2(3H)-one hydrochloride is used as a research chemical for studying the effects of cannabinoids on the brain and body. It helps researchers understand the mechanisms of action and potential therapeutic applications of cannabinoid receptor agonists.
Used in Pharmacology Research:
In the field of pharmacology, 5-(Aminomethyl)benzo[d]oxazol-2(3H)-one hydrochloride is used to investigate the potential risks and side effects associated with synthetic cannabinoids. This research is crucial for developing safer and more effective medications and for informing regulatory policies.
Used in Drug Development:
Although its use and sale are restricted, 5-(Aminomethyl)benzo[d]oxazol-2(3H)-one hydrochloride may still be used in drug development to create new medications with fewer side effects and lower potential for abuse. Researchers continue to study 5-(AMinoMethyl)benzo[d]oxazol-2(3H)-one hydrochloride to better understand its effects and develop safer alternatives.
Used in Toxicology Studies:
5-(Aminomethyl)benzo[d]oxazol-2(3H)-one hydrochloride is also used in toxicology studies to evaluate the potential dangers and side effects of synthetic cannabinoids. This research is essential for understanding the risks associated with these substances and for developing strategies to mitigate their harmful effects.
Check Digit Verification of cas no
The CAS Registry Mumber 903556-85-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,3,5,5 and 6 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 903556-85:
(8*9)+(7*0)+(6*3)+(5*5)+(4*5)+(3*6)+(2*8)+(1*5)=174
174 % 10 = 4
So 903556-85-4 is a valid CAS Registry Number.
903556-85-4Relevant academic research and scientific papers
HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS
-
Page/Page column 76, (2008/12/05)
The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.
